Apex Bioventures Acquisition Corp. has signed a definitive merger agreement with privately held Dynogen Pharmaceuticals Inc., in a stock deal valued at more than $140 million, based on Apex's share price of $7.27, sources involved in the negotiations said. (BioWorld Today)